0
0
6/16/23 at 3:20pm
Organization
Gavi.org
37 words
0
Comments
A phase 3 trial suggests the VLA1553 chikungunya vaccine candidate is safe, well tolerated and provokes strong antibody responses in 99% of recipients.
You are the first to view
https://www.gavi.org/vaccineswork/promising-trial-results-suggest-chikungunya-vaccine-could-be-within-reach
Create an account
or login to join the discussion